Gender-based differences of copeptin alone or combined with troponin for early rule-out of non-ST-elevation myocardial infarction.

Abstract

Little is known about the role of gender in the dual biomarker strategy using copeptin and troponin for the early rule-out of non-ST-elevation myocardial infarction (NSTEMI). We aimed to evaluate gender-based differences on copeptin levels, combined negative predictive value (NPV) and predictors of copeptin elevation at admission. Biomarkers were measured in 852 adult patients presenting to the emergency department with chest pain and suspected NSTEMI. Logistic regression analyses on predictors of copeptin elevation were evaluated by gender. Overall, 362 women (42.5%) and 490 men (57.5%) were included. Copeptin levels were higher in men (median 7.36pmol/L vs. 4.8pmol/L; P<.001). Men had a similar NPV (100%) as women (99.6%, CI: 98.8-100) using the dual biomarker rule-out strategy and when compared to troponin alone (men, NPV=98.7%, CI: 97.5-99.8; and women, NPV=98.7%, CI: 97.5-100). Multivariate logistic regression showed positive association of male gender with copeptin elevation (OR=2.37; CI: 1.61-3.49; P<.001). In men, diastolic blood pressure was a negative predictor of copeptin elevation (OR=0.98, 95% CI: 0.96-0.99), while positive predictors were current MI (OR=2.16, 95% CI: 1.19-3.91), chronic renal insufficiency (OR=3.58, 95% CI: 1.33-9.62), and atrial fibrillation (OR=2.56, 95% CI: 1.23-5.32), respectively (all P<.05). In women, current MI (OR=2.98, CI: 1.23-7.24), atrial fibrillation (OR=2.90, CI: 1.26-6.70) and syncope-like events (OR=7.56, CI: 2.26-25.30) were significant predictors of copeptin elevation. Men with suspected NSTEMI have higher copeptin levels. The dual biomarker rule-out strategy has a similar performance in both male and female patients. Certain predictors of copeptin elevation are gender-specific.